Literature DB >> 33414393

Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway.

Haibiao Xie1,2,3,4, Kaifang Ma1,2,3,4, Kenan Zhang1,2,3,4, Jingcheng Zhou1,2,3,4, Lei Li1,2,3,4, Wuping Yang1,2,3,4, Yanqing Gong5,6,7, Lin Cai8,9,10, Kan Gong11,12,13,14.   

Abstract

TP53 is a classic tumor suppressor, but its role in kidney cancer remains unclear. In our study, we tried to explain the role of p53 in kidney cancer through the p53-related enhancer RNA pathway. Functional experiments were used to explore whether P53-bound enhancer regions 2 (p53BER2) has a role in the cell cycle and senescence response of TP53-wild type (WT) renal cancer cells in vitro or vivo. RNA-sequencing was used to identify the potential target of p53BER2. The results showed that the expression level of P53BER2 was downregulated in renal cancer tissues and cell lines, further dual-luciferase experiments and APR-256-reactivated experiments showed p53BER2 expresses in a p53-dependent way. Moreover, knockdown p53BER2 could reverse nutlin-3-induced cytotoxic effect in TP53-WT cell lines. Further exploration showed the downregulation of p53BER2 could reverse nutlin-3-induced G1-arrest and senescence in TP53-WT cell lines. What is more, the knockdown of p53BER2 showed resistance to nutlin-3 treatment in vivo. Additionally, we found BRCA2 could be regulated by p53BER2 in vitro and vivo; further experiment showed p53BER2 could induce cell-cycle arrest and DNA repair by mediating BRCA2. In summary, the p53-associated enhancer RNA-p53BER2 mediates the cell cycle and senescence of p53 in TP53-WT renal cancer cells.

Entities:  

Year:  2021        PMID: 33414393      PMCID: PMC7791070          DOI: 10.1038/s41419-020-03229-8

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  50 in total

1.  eRNAs are required for p53-dependent enhancer activity and gene transcription.

Authors:  Carlos A Melo; Jarno Drost; Patrick J Wijchers; Harmen van de Werken; Elzo de Wit; Joachim A F Oude Vrielink; Ran Elkon; Sónia A Melo; Nicolas Léveillé; Raghu Kalluri; Wouter de Laat; Reuven Agami
Journal:  Mol Cell       Date:  2012-12-27       Impact factor: 17.970

2.  The location of endogenous wild-type p53 protein in 293T and HEK293 cells expressing low-risk HPV-6E6 fusion protein with GFP.

Authors:  Lina Sun; Xinxin Shen; Yan Liu; Ge Zhang; Jianchun Wei; Huijuan Zhang; Enming Zhang; Fengqin Ma
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2010-03-15       Impact factor: 3.848

3.  PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.

Authors:  Roza Zandi; Galina Selivanova; Camilla Laulund Christensen; Thomas Alexander Gerds; Berthe Marie Willumsen; Hans Skovgaard Poulsen
Journal:  Clin Cancer Res       Date:  2011-03-17       Impact factor: 12.531

4.  Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.

Authors:  R Nenutil; J Smardova; S Pavlova; Z Hanzelkova; P Muller; P Fabian; R Hrstka; P Janotova; M Radina; D P Lane; P J Coates; B Vojtesek
Journal:  J Pathol       Date:  2005-11       Impact factor: 7.996

5.  Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals.

Authors:  Mitchell Guttman; Ido Amit; Manuel Garber; Courtney French; Michael F Lin; David Feldser; Maite Huarte; Or Zuk; Bryce W Carey; John P Cassady; Moran N Cabili; Rudolf Jaenisch; Tarjei S Mikkelsen; Tyler Jacks; Nir Hacohen; Bradley E Bernstein; Manolis Kellis; Aviv Regev; John L Rinn; Eric S Lander
Journal:  Nature       Date:  2009-02-01       Impact factor: 49.962

6.  p53 mutations and MDM-2 amplification in renal cell cancers.

Authors:  Y Imai; T G Strohmeyer; M Fleischhacker; D J Slamon; H P Koeffler
Journal:  Mod Pathol       Date:  1994-09       Impact factor: 7.842

Review 7.  P53 abnormalities and outcomes in colorectal cancer: a systematic review.

Authors:  A J Munro; S Lain; D P Lane
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

8.  Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA.

Authors:  Nicolas Léveillé; Carlos A Melo; Koos Rooijers; Angel Díaz-Lagares; Sonia A Melo; Gozde Korkmaz; Rui Lopes; Farhad Akbari Moqadam; Ana R Maia; Patrick J Wijchers; Geert Geeven; Monique L den Boer; Raghu Kalluri; Wouter de Laat; Manel Esteller; Reuven Agami
Journal:  Nat Commun       Date:  2015-03-27       Impact factor: 14.919

9.  BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors.

Authors:  Timo Reisländer; Emilia Puig Lombardi; Florian J Groelly; Ana Miar; Manuela Porru; Serena Di Vito; Benjamin Wright; Helen Lockstone; Annamaria Biroccio; Adrian Harris; Arturo Londoño-Vallejo; Madalena Tarsounas
Journal:  Nat Commun       Date:  2019-07-17       Impact factor: 14.919

Review 10.  Interplay between Fanconi anemia and homologous recombination pathways in genome integrity.

Authors:  Johanna Michl; Jutta Zimmer; Madalena Tarsounas
Journal:  EMBO J       Date:  2016-04-01       Impact factor: 11.598

View more
  16 in total

1.  LINC02381-ceRNA exerts its oncogenic effect through regulation of IGF1R signaling pathway in glioma.

Authors:  Hossein Nemati; Masoumeh Fakhre-Taha; Amir-Reza Javanmard; Amin Jahanbakhshi; Seyed Javad Mowla; Bahram M Soltani
Journal:  J Neurooncol       Date:  2022-04-23       Impact factor: 4.130

Review 2.  Emerging role of m6A modification in osteogenesis of stem cells.

Authors:  Zi Zou; Tiantian He; Ying Liu; Leliang Zheng; Yancheng Zhong; Yuqing Mo; Shuping Peng; Cijun Shuai
Journal:  J Bone Miner Metab       Date:  2022-01-29       Impact factor: 2.626

3.  Blockade of exosome release alters HER2 trafficking to the plasma membrane and gives a boost to Trastuzumab.

Authors:  Leila Asef-Kabiri; Hamzeh Sarvnaz; Alireza Ghanavatinejad; Reza Hosseini; Fatemeh Rezayat; Nahid Eskandari; Mohammad Esmaeil Akbari
Journal:  Clin Transl Oncol       Date:  2022-08-26       Impact factor: 3.340

Review 4.  Differential molecular mechanistic behavior of HDACs in cancer progression.

Authors:  Tashvinder Singh; Prabhsimran Kaur; Paramdeep Singh; Sandeep Singh; Anjana Munshi
Journal:  Med Oncol       Date:  2022-08-16       Impact factor: 3.738

Review 5.  Prospect of exosomal circular RNAs in breast Cancer: presents and future.

Authors:  Elham Zokaei; Farzaneh Darbeheshti; Nima Rezaei
Journal:  Mol Biol Rep       Date:  2022-05-09       Impact factor: 2.742

Review 6.  Aurora B kinase: a potential drug target for cancer therapy.

Authors:  Azaj Ahmed; Anas Shamsi; Taj Mohammad; Gulam Mustafa Hasan; Asimul Islam; Md Imtaiyaz Hassan
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-28       Impact factor: 4.553

Review 7.  Perspective: Treatment for Disease Modification in Chronic Neurodegeneration.

Authors:  Thomas Müller; Bernhard Klaus Mueller; Peter Riederer
Journal:  Cells       Date:  2021-04-12       Impact factor: 6.600

8.  miR-106b-5p Intensifies the Proliferative Potential of Spermatogonial Stem Cells as a Prerequisite for Male Infertility Treatment.

Authors:  Amir Hossein Hasani Fard; Mahmoud Valizadeh; Zohreh Mazaheri; Seyed Jalil Hosseini
Journal:  Reprod Sci       Date:  2022-03-23       Impact factor: 3.060

9.  Inflammatory markers in chronic kidney disease and end stage renal disease patients.

Authors:  Mahmoud M Zakaria; Safaa A Derbala; Ayman E Salem; Amgad E El-Agroudy; Fatma M El-Tantawy
Journal:  Mol Biol Rep       Date:  2021-09-01       Impact factor: 2.316

Review 10.  The Multifaceted Nature of Nucleobindin-2 in Carcinogenesis.

Authors:  Anna Skorupska; Rafał Lenda; Andrzej Ożyhar; Dominika Bystranowska
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.